Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves IntraBio’s Aqneursa as First Treatment for Ataxia-Telangiectasia
Follow us on:
Breaking News
30-10-2026
Breaking News
Breaking News

FDA Approves IntraBio’s Aqneursa as First Treatment for Ataxia-Telangiectasia

 
FDA Approves IntraBio’s Aqneursa as First Treatment for Ataxia-Telangiectasia

It is the second FDA-approved indication for Aqneursa, following Niemann-Pick disease type C.
Read More >>

test

Breaking News

AustinPx KinetiSol Earns FDA AMT Designation

Solvent-free technology expands manufacturing options for poorly soluble oral drug candidates.

Breaking News
Promotions & Moves

Longhorn Vaccines and Diagnostics Names Dr. Vijay Singh Chief Scientific Officer

Singh will help drive expansion of Longhorn’s PrimeStore MTM, a sample collection device.

Breaking News
Collaborations & Alliances

ExploRNA, Łukasiewicz Research Network Partner on GMP Manufacturing of Next-Gen mRNA Cap Analogs

Łukasiewicz, known for advanced chemical synthesis and production scaling capabilities, will help ExploRNA ramp up its mRNA manufacturing.

Breaking News
Promotions & Moves

Codis Promotes Steven Facer to Chief Commercial Officer

Facer offers 30+ years of leadership experience across pharmaceuticals, medical devices, and packaging.